Allogene Therapeutics Inc (NASDAQ:ALLO) Forecasted to Earn Q1 2020 Earnings of ($0.66) Per Share

Allogene Therapeutics Inc (NASDAQ:ALLO) – Research analysts at William Blair issued their Q1 2020 earnings estimates for shares of Allogene Therapeutics in a report released on Monday, April 15th, Zacks Investment Research reports. William Blair analyst R. Prasad anticipates that the company will post earnings per share of ($0.66) for the quarter. William Blair has a “Buy” rating on the stock. William Blair also issued estimates for Allogene Therapeutics’ Q2 2020 earnings at ($0.68) EPS, Q3 2020 earnings at ($0.69) EPS and Q4 2020 earnings at ($0.74) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Tuesday, May 7th. The company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.08.

Several other equities analysts also recently weighed in on the company. JPMorgan Chase & Co. reissued a “hold” rating and set a $29.00 target price on shares of Allogene Therapeutics in a research report on Monday, March 11th. Piper Jaffray Companies initiated coverage on Allogene Therapeutics in a research report on Friday, March 29th. They set an “overweight” rating and a $50.00 target price on the stock. Cowen reissued a “buy” rating on shares of Allogene Therapeutics in a research report on Friday, March 8th. Raymond James assumed coverage on Allogene Therapeutics in a research report on Thursday, March 14th. They set an “outperform” rating and a $40.00 target price on the stock. Finally, Oppenheimer assumed coverage on Allogene Therapeutics in a research report on Friday, May 3rd. They issued an “outperform” rating and a $45.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $38.00.

Shares of NASDAQ ALLO traded up $0.29 during trading hours on Wednesday, hitting $30.31. 419,948 shares of the company traded hands, compared to its average volume of 392,861. The company has a market cap of $3.65 billion and a P/E ratio of -4.61. Allogene Therapeutics has a 12 month low of $21.67 and a 12 month high of $35.55.

Institutional investors have recently made changes to their positions in the business. Barclays PLC bought a new position in Allogene Therapeutics in the 4th quarter valued at $27,000. Legal & General Group Plc bought a new position in Allogene Therapeutics in the 4th quarter valued at $89,000. Partner Investment Management L.P. purchased a new stake in shares of Allogene Therapeutics in the 4th quarter worth $135,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Allogene Therapeutics in the 1st quarter worth $136,000. Finally, Citigroup Inc. purchased a new stake in shares of Allogene Therapeutics in the 4th quarter worth $152,000. 51.59% of the stock is currently owned by institutional investors.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?

Get a free copy of the Zacks research report on Allogene Therapeutics (ALLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.